Nishizono 1994.

Methods	Randomisation: randomised, no further details. Allocation: procedure not described. Blinding: n.i., probably open. Duration: 4 weeks. Design: n.i., Location: multicentre. Setting: n.i.,
Participants	Diagnosis: schizophrenia (ICD‐10). N = 109. Gender: n.i., Age: n.i., History: duration stable ‐ n.i., duration ill ‐ n.i., number of previous hospitalisations ‐ n.i., age at onset ‐ n.i., severity of illness ‐ n.i., baseline antipsychotic dose ‐ n.i.,
Interventions	1. Haloperidol: flexible dose, allowed dose range n.i., dose max. 21 mg/day. N = 57. 2. Chlorpromazine: flexible dose, allowed dose range n.i., dose max. 450 mg/day. N = 52. Other medication: n.i..
Outcomes	Response to treatment: at least 50% reduction in BPRS total score. Unable to use: Mental state: BPRS (incomplete data, no SD). Global state: Global Assessment Scale (incomplete data, no SD). Leaving the study early (no data available).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Procedure not described.
Blinding of participants and personnel (performance bias) All outcomes	High risk	n.i., probably open.
Blinding of outcome assessment (detection bias) All outcomes	High risk	n.i., probably open.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not enough information to permit judgement about incomplete outcome data.
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement about selective reporting.
Other bias	Unclear risk	Insufficient information about other sources of bias.